Indivior and Supernus Forge a Merger of Equals, Creating a $2.2B CNS Biopharma Powerhouse
INDV has more than doubled off its 52-week low of $19.31.
Summary
Indivior and Supernus Pharmaceuticals have announced a merger of equals, blending complementary CNS portfolios into a company with ~$2.2B in annual revenue. A $1B special dividend will be paid to Indivior stockholders before closing, and Supernus CEO Jack Khattar will lead the combined entity.
Key Events · M&A and Partnerships · INDV
-
Merger of Equals Announced
Under a definitive all-stock merger agreement, Supernus stockholders will receive 1.5401 Indivior shares for each Supernus share, resulting in Indivior stockholders owning ~56.5% and Supernus stockholders ~43.5% of the combined company.
-
$1B Special Dividend to Indivior Stockholders
A $1 billion special cash dividend will be paid to Indivior stockholders prior to closing, funded by $650 million in committed debt financing from Citibank N.A. and existing cash.
-
Leadership and Governance
Jack Khattar, currently Supernus CEO, will become President and CEO of the combined company, while Tony Kingsley, an Indivior director, will serve as Board Chair. The board will comprise eight directors, split evenly between the two companies.
-
Expected $125M in Annual Cost Synergies
The combined company anticipates realizing $125 million in annual cost synergies, which will enhance free cash flow and provide financial flexibility for both internal and external growth.
Analysis · INDV · Life Sciences
A definitive all-stock merger of equals will unite Indivior and Supernus Pharmaceuticals, forming a diversified CNS portfolio with approximately $2.2 billion in annual revenues and an expected $125 million in annual cost synergies. Before closing, Indivior stockholders will receive a $1 billion special cash dividend, backed by $650 million in new debt and existing cash. The fixed exchange ratio of 1.5401 Indivior shares per Supernus share gives Indivior stockholders roughly 56.5% ownership of the combined entity. Pending stockholder and regulatory approvals, the deal is set to close in Q4 2026—a transformative move that reshapes both companies and establishes a scaled CNS biopharmaceutical leader.
At the time of this filing, INDV was trading at $40.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $19.31 to $42.81. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.